ALPHARETTA, Ga., Sept. 4, 2015 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV), today announced the Company's upcoming financial conferences schedule:
- Rodman & Renshaw 17th Annual Global Investment Conference: Chairman Kevin Richardson will present on Thursday, September 10, 2015 at 2:35 p.m. ET and will also be available for one-on-one meetings with the investment community. The conference is being held September 8-10, 2015, at the St. Regis Hotel in New York City.
- Singular Research 10th Annual Best of the Uncovereds Conference: Chairman Kevin Richardson will present at a time to be announced and will also be available for one-on-one meetings with the investment community. The conference is being held September 17, 2015 at the Luxe Hotel in Los Angeles, CA
- Aegis Capital Corp 2015 Growth Conference: Chairman Kevin Richardson will present at a time to be announced and will also be available for one-on-one meetings with the investment community. The conference is being held October 7-9, 2015 at The Encore at Wynn in Las Vegas, NV.
Company management will be available for one-on-one meetings with investors participating in the conferences. For those who would like to schedule an appointment with SANUWAVE's management, please contact DC Consulting by phone, (407) 792-3333, or email firstname.lastname@example.org.
The most current schedule for our financial conferences will be accessible on the investor relations section of our website at www.sanuwave.com. The schedule is subject to change as we present at additional conferences.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
CONTACT: Todd Markey IR Partners 818-280-6800 email@example.com Daniel Conway DC Consulting, LLC 407-792-3333 firstname.lastname@example.org SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 617-778-9223 email@example.com
Source:SANUWAVE Health, Inc.